Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Earlier in April, Biodel management updated the timeline for the development of its ultra-rapid-acting insulin candidates. As a reminder, in October 2010 the company's...
In late July, pharmacy benefit managers (PBMs) Express Scripts and Medco Health Solutions announced their plans to merge. As background, PBMs process prescriptions for...
In late June, the European Medicines Agency (EMA) approved Amylin/Eli Lilly/Alkermes’ once-weekly injectable drug Bydureon for type 2 diabetes. We’ve been waiting for...
In October, Novo Nordisk announced that it had submitted its two new “next-generation” insulin products for approval in both the US and Europe (and Japan to follow soon...
In June, Insulet announced the acquisition of Neighborhood Diabetes, a medical equipment distributor that specializes in consumer sales of diabetes supplies. The company...
Over the past several years, the use of GLP-1 drugs (such as Byetta and Victoza) together with basal insulins (such as Lantus and Levemir) as a treatment for type 2...
In previous issues, we’ve documented the arduous journey of Orexigen’s anti-obesity drug Contrave through the regulatory process. In December, an FDA Advisory Committee...
What are going to be the big headlines for 2012? What will be the impact of Bydureon, the latest once-weekly drug for people with type 2 diabetes?
On June 16, FDA officials provided an update on its safety review of Takeda’s Actos (pioglitazone), announcing that going forward, prescribing information for Actos will...
On January 27, the Food and Drug Administration (FDA) granted approval to Bydureon, a new drug for type 2 diabetes that is injected once a week. Approved last year in...
Kelly’s take on the maddeningly slow FDA approval process and why things are probably getting better.
Kerri Morrone Sparling reflects on the true meaning of ‘need’ in the global diabetes community…
In June, pharmaceutical giant Bristol-Myers Squibb (BMS) and its partner AstraZeneca (AZ) acquired the important biotech company Amylin for a cool $7 billion, which we...
On November 8, an FDA advisory panel voted 8-4 to recommend approval of Novo Nordisk’s ultra-long-acting basal insulin degludec (to be marketed under the name “Tresiba...
Can a drug for type 2 diabetes work for those with type 1? How will a new basal insulin compare to Lantus?
Dr. Arya Sharma highlights the most important weight loss tip everyone should know and why weight maintenance is a major achievement.
The past few months have seen the approval of a pair of new drugs designed to treat obesity, Arena’s Belviq (see new now next in diaTribe #44) and Vivus’ Qsymia (see new...
How can the FDA change its view on drug approvals to give patients access to better therapies?
Many people with diabetes fear eye diseases leading to blindness. In diabetic macular edema (DME), the leading cause of blindness among working-age Americans (over 560,...
In late November, Vivus launched its Get Started! Program , which gives potential users of its weight management medication Qsymia a chance to try the drug free for two...

Pages